Volker Wacheck

5.2k total citations
113 papers, 3.6k citations indexed

About

Volker Wacheck is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Volker Wacheck has authored 113 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Molecular Biology, 30 papers in Oncology and 26 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Volker Wacheck's work include PI3K/AKT/mTOR signaling in cancer (20 papers), Lung Cancer Treatments and Mutations (17 papers) and RNA Interference and Gene Delivery (16 papers). Volker Wacheck is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (20 papers), Lung Cancer Treatments and Mutations (17 papers) and RNA Interference and Gene Delivery (16 papers). Volker Wacheck collaborates with scholars based in Austria, United States and Japan. Volker Wacheck's co-authors include Burkhard Jansen, Hubert Pehamberger, Edgar Selzer, Daniel Cejka, Trevor Lucas, Brett P. Monia, Elisabeth Heere‐Ress, Hermine Schlagbauer‐Wadl, Sabine Strommer and Doris Losert and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Volker Wacheck

109 papers receiving 3.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Volker Wacheck Austria 35 2.3k 1.0k 496 480 474 113 3.6k
T.R. Jeffry Evans United Kingdom 36 1.8k 0.8× 1.9k 1.9× 333 0.7× 686 1.4× 802 1.7× 107 4.4k
Giulio Francia United States 31 1.5k 0.6× 1.5k 1.5× 346 0.7× 540 1.1× 849 1.8× 69 3.2k
Timothy B. Lowinger United States 20 1.3k 0.5× 843 0.8× 244 0.5× 262 0.5× 475 1.0× 53 2.7k
David Propper United Kingdom 24 1.1k 0.5× 1.3k 1.3× 662 1.3× 374 0.8× 532 1.1× 78 3.1k
Richard Kendall United States 24 1.8k 0.8× 837 0.8× 324 0.7× 268 0.6× 476 1.0× 43 3.0k
Alison Joly United States 18 1.5k 0.7× 902 0.9× 313 0.6× 624 1.3× 432 0.9× 26 2.9k
Devalingam Mahalingam United States 41 2.9k 1.3× 2.0k 2.0× 655 1.3× 711 1.5× 922 1.9× 186 5.4k
Fang Wang China 36 2.1k 0.9× 2.2k 2.1× 475 1.0× 1.0k 2.1× 869 1.8× 160 4.2k
Laura K. Shawver United States 26 3.4k 1.5× 2.0k 1.9× 363 0.7× 562 1.2× 1.2k 2.5× 47 5.1k
S. Gail Eckhardt United States 27 1.8k 0.8× 1.2k 1.2× 197 0.4× 466 1.0× 620 1.3× 54 2.9k

Countries citing papers authored by Volker Wacheck

Since Specialization
Citations

This map shows the geographic impact of Volker Wacheck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Volker Wacheck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Volker Wacheck more than expected).

Fields of papers citing papers by Volker Wacheck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Volker Wacheck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Volker Wacheck. The network helps show where Volker Wacheck may publish in the future.

Co-authorship network of co-authors of Volker Wacheck

This figure shows the co-authorship network connecting the top 25 collaborators of Volker Wacheck. A scholar is included among the top collaborators of Volker Wacheck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Volker Wacheck. Volker Wacheck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heymach, John V., Helena A. Yu, Benjamin Besse, et al.. (2025). REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC. Future Oncology. 21(5). 549–556. 3 indexed citations
2.
3.
Meric‐Bernstam, Funda, Antoine Hollebecque, Junji Furuse, et al.. (2024). Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients. Clinical Cancer Research. 30(8). 1466–1477. 8 indexed citations
4.
Yu, Helena A., Benjamin Besse, Ying Cheng, et al.. (2024). REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations.. Journal of Clinical Oncology. 42(16_suppl). TPS8670–TPS8670. 1 indexed citations
5.
6.
Goyal, Lipika, Daniel DiToro, Antoine Hollebecque, et al.. (2024). Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling. Annals of Oncology. 36(4). 414–425. 2 indexed citations
7.
Sweeney, Christopher J., Ivor Percent, Sunil Babu, et al.. (2022). Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 28(11). 2237–2247. 31 indexed citations
8.
9.
Kondo, Shunsuke, Masaomi Tajimi, Kōichi Inoue, et al.. (2020). Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer. Investigational New Drugs. 38(6). 1836–1845. 5 indexed citations
10.
Harding, James J., Andrew X. Zhu, Todd M. Bauer, et al.. (2019). A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. Clinical Cancer Research. 25(17). 5202–5211. 32 indexed citations
11.
Scagliotti, Giorgio V., Denis Moro‐Sibilot, Jens Kollmeier, et al.. (2019). A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients. Journal of Thoracic Oncology. 15(1). 80–90. 60 indexed citations
12.
Bendell, Johanna C., Anna M. Varghese, David M. Hyman, et al.. (2018). A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. Clinical Cancer Research. 24(14). 3253–3262. 81 indexed citations
13.
Smith, Michèle C., Mary M. Mader, James A. Cook, et al.. (2016). Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth. Molecular Cancer Therapeutics. 15(10). 2344–2356. 62 indexed citations
14.
Rosen, Lee S., Jonathan W. Goldman, Alain P. Algazi, et al.. (2016). A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. Clinical Cancer Research. 23(8). 1910–1919. 57 indexed citations
15.
Johnson, Melissa L., Volker Wacheck, Maen Hussein, et al.. (2016). A phase 2 study of LY3023414 and necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi441–vi441. 3 indexed citations
16.
Fuereder, Thorsten, Thomas Wanek, Doris Hoeflmayer, et al.. (2011). Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake. Clinical Cancer Research. 17(16). 5322–5332. 31 indexed citations
17.
Willmann, Michael, Volker Wacheck, Jonathan D. Buckley, et al.. (2009). Characterization of NVX‐207, a novel betulinic acid‐derived anti‐cancer compound. European Journal of Clinical Investigation. 39(5). 384–394. 45 indexed citations
18.
Sieghart, Wolfgang, Susan K. Fellner, Thomas Reiberger, et al.. (2009). Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma. Digestive and Liver Disease. 41(12). 902–906. 24 indexed citations
19.
Wacheck, Volker & Uwe Zangemeister‐Wittke. (2006). Antisense molecules for targeted cancer therapy. Critical Reviews in Oncology/Hematology. 59(1). 65–73. 35 indexed citations
20.
Pratscher, Barbara, Doris Losert, Hubert Pehamberger, Markus Mueller, & Volker Wacheck. (2005). Quantitative single-cell analysis of target protein expression relative to human/murine tissue distribution in human xenografts for optimizing development of gene expression modulating therapeutics. Cancer Research. 65. 906–906. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T.R. Jeffry Evans Breakdown of academic impact, for papers by Giulio Francia Breakdown of academic impact, for papers by Timothy B. Lowinger Breakdown of academic impact, for papers by David Propper Breakdown of academic impact, for papers by Richard Kendall Breakdown of academic impact, for papers by Alison Joly Breakdown of academic impact, for papers by Devalingam Mahalingam Breakdown of academic impact, for papers by Fang Wang Breakdown of academic impact, for papers by Laura K. Shawver Breakdown of academic impact, for papers by S. Gail Eckhardt
Rankless by CCL
2026